
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: systematic review and network meta-analysis
Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Showing 4 citing articles:
Analysis of the migraine characteristics in the perimenopause
D. A. Klimentova, Г. Р. Табеева
Neurology neuropsychiatry Psychosomatics (2025) Vol. 17, Iss. 1, pp. 16-23
Open Access
D. A. Klimentova, Г. Р. Табеева
Neurology neuropsychiatry Psychosomatics (2025) Vol. 17, Iss. 1, pp. 16-23
Open Access
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment
Lanfranco Pellesi, Budour Jedie, Fadia Barhum, et al.
Pain Management (2025), pp. 1-6
Closed Access
Lanfranco Pellesi, Budour Jedie, Fadia Barhum, et al.
Pain Management (2025), pp. 1-6
Closed Access
Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice
Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, et al.
Neurology International (2025) Vol. 17, Iss. 5, pp. 62-62
Open Access
Takafumi Tanei, Shun Yamamoto, Satoshi Maesawa, et al.
Neurology International (2025) Vol. 17, Iss. 5, pp. 62-62
Open Access